Background: The Italian severe/uncontrolled asthma (SUA) web-based registry
| INTRODUCTION
Severe asthma is of remarkable interest for the scientific community, as documented by the work of some research groups in United States 1,2 and Europe. [3] [4] [5] The reasons for this large interest are many. First of all, around 10% of asthmatic patients are uncontrolled or refractory to the treatment. These patients with severe asthma are responsible for a relevant socioeconomic burden, in terms of direct costs related to out-/inpatient treatments and indirect costs related to the quality of life worsening and work disability. These patients account for 50% of asthma total costs. 6, 7 Another reason lies in the pathogenesis of severe asthma: there is a need for a better understanding as most mechanisms underlying asthma severity and therapy resistance are still unclear. To collect elements for characterizing the disease (clinical, epidemiological, functional, inflammatory features) may help to define the severe asthma phenotypes and to improve treatment. 8 The third reason is that patients with severe/uncontrolled asthma (SUA) poorly respond to standard therapy, and, often, an acceptable symptom control is achieved only through regular intake of oral corticosteroids (OCS). 9 Introduction of new biological drugs might help in controlling the disease, a goal not achievable with the available therapy.
In spite of the socioeconomic burden, an estimate of the real impact of SUA has been obtained so far only from selected centers in Italy 10 and an evaluation of the disease burden throughout all Italian regions is not available. Few experiences have been developed in other countries. A need remains for a better understanding and management of difficult-to-treat asthmatic patients. [1] [2] [3] [4] [5] Within this framework, the Italian Medicines Agency (AIFA)
funded the AGAVE project (Severe asthma: epidemiological and clinical cohorts follow-up by registry and questionnaires; therapeutic appropriateness and outcome assessment, according to GINA guidelines) aimed at assessing the effectiveness of therapeutic strategies for SUA patients, according to GINA guidelines, 11 in epidemiological and clinical samples, through the implementation of an online registry. The aims were to (1) (26.3%). 4.1% of subjects received specific immunotherapy. According to the specialists' opinion, 86% had a good adherence to antiasthma therapy and 93.5% had a correct use of inhalers (Table 3) .
| Comorbidities
Several comorbidities were observed: The most commonly reported were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasal polyps and allergic conjunctivitis (30.2%) ( Figure 1A ,B).
| Asthma control
55.7% of patients had at least one exacerbation in the last 12 months; of them, 90.3% underwent OCS courses (mean frequency: 2.7 times in the last 12 months). 7.3% had at least one hospitalization during the previous year, while 9.7% at least one emergency department (ED) visit (Table 3 ).
According to the 2010 WHO definition of severe/uncontrolled asthma, 12 1% of the patients were uncontrolled with difficult-totreat severe asthma (group 2), 84% were asthmatic for which control was not achieved despite the highest level of recommended treatment (group 3a), and 15% were controlled only with the highest level of recommended treatment (group 3b) ( ; the asthma control questionnaire (ACQ) and the asthma control test (ACT) scores confirmed a poor disease control with a mean value of 2.1 for ACQ and 19.4 for ACT (classifying patients with a score >1.5 for ACQ and <20 for ACT as uncontrolled 15, 16 ) ( Table 3 ). (Table S1 ).
| Sensitivity analysis
Only few differences were found in the clinical data: a higher mean level of FEV 1 /FVC (72.7 vs 66.5), a lower mean value of FVC (88.6 vs 94.5), a lower median percentage of blood eosinophils (4.2% vs 5.3%), and a higher frequency of positive skin prick tests (98.1% vs 59.3%) in patients treated with omalizumab (Table S2) .
As regards the comparison among allergic and nonallergic patients, few differences existed in the pharmacological treatments ( Step 1 0.5
Step 2 0.2
Step 3 9.2
Step 4a b 12.3
Step 4b c 14.0
Step Step 4a: subjects using only medium/high dose of combination LABA + ICS. Step 4b: subjects using medium/high dose of combination LABA + ICS plus a third controller. 
| SUA patients' description
Since the AGAVE project started in 2010, we had to take into account diagnostic criteria published until such year. In particular, in order to select patients to be inserted in the registry, we considered the criteria reported in the decision-making steps proposed by the experts participating in the World Health Organization Consultation on Severe Asthma. 12 Our data were compared to those observed in the most impor- (Table 5 ).
| General characteristics
Overall, the population included in the registries had similar characteristics in terms of gender (majority of women) and BMI (overweight); mean age ranged between 41 and 55 years. [1] [2] [3] [4] [5] We found a late-onset asthma (starting at age >40 years) in 29.8% of patients, as in the Belgian registry. 5 Our data showed a mean difference between the age of symptoms onset and the age of diagnosis of about 4 years. This diagnostic delay could be due to the communication difficulties between patients and physicians; indeed, most patients do not report their bronchial symptoms to the general practitioner remaining undiagnosed. On the other hand, patients with respiratory problems and reduced lung function are not always recognized as such, 17 may be due to a lack of guidelines awareness or implementation. 18 The proportion of current smokers (2.8%) in Italian patients was lower than that observed in the other studies/registries; on the contrary, comparable results were found for past smoking history (about 30%). 
| Lung function and inflammatory characteristics
Overall, there was a moderate obstructive airway pattern, with values (mean FEV 1 % pred 75.1%) similar to those of multicenter studies, 2,3 but higher than those of the SARP study 1 and severe asthma registries. 4, 5 The mean value of FEV 1 /FVC ratio was 70%, slightly higher than in the other studies/registries, 1,4,5 but lower than in the ENFUMOSA study. 3 Italian patients had evidence of eosinophilic inflammation in line with the other registries. 4, 5 Data from induced sputum samples, available only from Pisa clinical center, showed a higher proportion of eosinophilic asthma with respect to the other severe asthma studies/registries, [3] [4] [5] but in line with other findings suggesting that eosinophilic asthma is more frequently encountered in severe asthma than in moderate one 19 and in late-onset asthma. 20 An elevated IgE level was found, higher than in the other studies/registries. 
Treatment

GINA step (%)
.000
Step 1, 2 or 3 6.7 16.3
Step 4a* 16.2 10.6
Step 4b* 22.4 6.3
Step 5 SUA patients, as expected, were mainly treated according to GINA guidelines step 4 or 5 (26.3% and 60.7%, respectively).
11
About 10% of patients in the Italian Registry received a treatment not recommended by GINA guidelines for severe asthma (step 1, 2, or 3) due to the fact that patients using anti-IgE, after reaching high levels of asthma control, were likely prescribed to reduce either the uptake of OCS or the ICS dose. Indeed, a recent meta-analysis showed that anti-IgE-treated patients more likely underwent the withdrawal of corticosteroid therapy. 21 Italian patients showed high level of IgE, atopic status, and an eosinophilic inflammation pattern both at systemic and at airways level, confirming the importance of using biological treatments.
| Comorbidities
Comorbidities observed among Italian patients were similar to those evidenced in other studies on similar populations, 1,4,5 except for nasal polyps and aspirin hypersensitivity that were more frequent in RItA Registry.
| Asthma control
About 40% of Italian patients had a poor asthma control according to GINA guidelines, confirmed by ACT and ACQ scores. These data were in line with the Belgian registry. 5 Over 50% of patients reported at least one exacerbation in the previous 12 months. showed borderline values.
The relevant burden that obesity, upper airway disease, and psychiatric disorders may cause on asthma symptoms, pulmonary function, and response to treatment has been recently reported in another Italian study. 22 Severe asthmatic patients with comorbidities had a higher frequency of poorly controlled asthma compared to those without. 22 Obesity is a risk factor for asthma, and it is associated with disease severity, a poor response to corticosteroids, and worse clinical control (ie, more symptomatic days, use of rescue medication, direct/indirect costs). 23 Moreover, obesity, central adiposity, and metabolic syndrome aspects have been implicated in the pathogenesis of the adult-onset asthma phenotype. 24 In Europe, a study on difficult-to-treat asthma showed that psychological disorders were significantly associated with frequent exacerbations (OR 10.8). 25 A more recent US study showed that mental disorders were significantly associated with the increased risk of asthma-specific hospitalizations and exacerbations, with the highest values in the age groups 18-45 years (incident rate 2.05 and 1.44, respectively).
26
Asthma and nasal polyps frequently coexist and share similar features of inflammation and remodeling. 27 Asthmatic subjects with chronic rhinosinusitis and nasal polyps had more frequently a poor control and increased airway obstruction compared with those without chronic rhinosinusitis and nasal polyps. 28 In the present study, notwithstanding the high rate of antiasthma therapy adherence, patients with a partial/poor adherence had a higher exacerbations risk (OR 2.54), in line with a recent review showing that a good adherence was associated with lower risk of severe asthma exacerbations. 29 Indeed, adherence to antiasthma controller medications is one of the key drivers to improve persistent asthma management. 30 Italian patients in treatment with anti-IgE had a significantly lower risk of exacerbations (OR 0.26, ie, fourfold less than subjects not using IgE), after adjusting for comorbidity, allergic asthma, and therapy adherence. These data are in line with those reported in a recent review showing the anti-IgE treatment-positive effect. 31 Moreover, an Italian study on severe asthmatic patients showed a significant reduction in exacerbations and health services use during omalizumab treatment compared with the period before treatment. 22 The anti-IgE effect on the reduction in exacerbation risk, independently of allergic status, is in line with recent data showing that anti-IgE may be beneficial for SUA patients in whom atopy status cannot be identified 32 and in patients with intrinsic asthma. 33 Intrinsic asthma can display elevated concentrations of total serum IgE and of allergenspecific IgE antibodies in the airways, despite negative skin prick tests. 34 On the other hand, anti-IgE could prevent asthma exacerbations by strengthening innate immunity, rather than by reducing allergy. 33 
| Strengths and limitations
Our study was characterized by an elevated number of enrolled patients, coming from 27 centers well distributed over the country; thus, they may be considered representative of all the Italian SUA patients.
A detailed and thorough questionnaire, based on the main items of the GINA guidelines, was used to obtain an exhaustive patients' characterization. It was reviewed and approved by an internal board comprising pneumologists, allergists, and epidemiologists.
A potential bias of this study was the enrollment of about 50%
of the sample undergoing anti-IgE treatment, a higher percentage with respect to the clinical practice. These patients have different characteristics from those not using this treatment; indeed, the Italian regulation defines the eligible patients for treatment with antiIgE as follows: SUA patients undergoing LABA + ICS treatment, with a high level of total IgE and positivity to perennial allergens.
Nevertheless, our data showed consistency with those of the other registries and multicenter studies on severe asthma.
| CONCLUSION S
In summary, this is the first paper presenting demographic and clinical data from a wide Italian population sample of SUA patients. Further information will derive from the ongoing analyses of the 3-to 12-month follow-up.
Comparisons to multicenter studies and available registries on severe asthma showed data consistency across European and American populations. 35 An international effort in the implementation and data analyses of registries on SUA patients could be an added value to better understand the clinical features and to better manage difficult-to-treat asthmatic patients, which represent a non-negligible socioeconomic burden for the health services. Asthma research collaboration was recently promoted and fostered by the European Respiratory Society. 36 Italian data showed the need for reducing the diagnostic delay, through an early detection of asthma and a subsequent early treatment, in order to improve the long-term prognosis of these patients, probably preventing the development of long-term modifications, such as remodeling, with a subsequent further impairment in pulmonary function. 17 It is to point out that a new Severe Asthma Network in Italy is under development; thus, our RItA data will provide a basis for future comparisons. 37 MAIO ET AL.
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Moreover, the future availability in Italy of new biologic drugs with different specific targets requires an effort in phenotyping patients with severe asthma, in order to provide them a tailored treatment, as in the ongoing Refractory Asthma Stratification Programme (RASP-UK) aimed at developing a clinical model to assess and phenotype patients with severe asthma. 38 
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